SCHEMBL17763473

SCHEMBL17763473

C[C@@H]1CCN(Cc2ccccc2)CCN1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACHE P22303 4/20 0.67
SIGMAR1 Q99720 2/20 0.61
CCR3 P51677 1/20 0.56
DRD2 P14416 2/20 0.53
DRD4 P21917 2/20 0.53
DRD3 P35462 2/20 0.53
MC4R P32245 1/20 0.51
BACE1 P56817 3/20 0.51
BCHE P06276 1/20 0.51
LMNA P02545 1/20 0.50
POLB P06746 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 1/20 0.49
CXCR4 P61073 1/20 0.49
HTR2A P28223 1/20 0.49
HRH3 Q9Y5N1 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17830169 1.00 ACHE (0.67) ACHESIGMAR1CCR3DRD2DRD4
SCHEMBL17495605 1.00 ACHE (0.67) ACHESIGMAR1CCR3DRD2DRD4
Hydrochloric Acid SCHEMBL28538225 0.98 ACHE (0.65) ACHESIGMAR1CCR3DRD2DRD4
Cadaverine Tartrate SCHEMBL31269600 0.88 ACHE (0.52) ACHESIGMAR1DRD4BCHEMEN1
SCHEMBL1826258 0.85 SIGMAR1 (0.58) ACHESIGMAR1MC4RBACE1BCHE
SCHEMBL1307820 0.85 SIGMAR1 (0.58) ACHESIGMAR1MC4RBACE1BCHE
SCHEMBL1471041 0.85 SIGMAR1 (0.58) ACHESIGMAR1MC4RBACE1BCHE
Hydrochloric Acid SCHEMBL18788467 0.83 SIGMAR1 (0.56) ACHESIGMAR1MC4RBACE1BCHE
SCHEMBL10720875 0.83 ACHE (0.57) ACHESIGMAR1CCR3DRD2DRD4
Ammonia Solution, Strong SCHEMBL2945383 0.82 ACHE (0.96) ACHESIGMAR1CCR3DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688773-A1 PROCESS FOR THE PREPARATION OF SUVOREXANT Biophore India Pharmaceuticals Pvt. Ltd. (IN) 2026-02-11 EP claimed
CN-119264064-A Synthetic method of high chiral purity suvorexant intermediate 安徽联创生物医药股份有限公司 2025-01-07 CN claimed
WO-2024201424-A1 PROCESS FOR THE PREPARATION OF SUVOREXANT BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) 2024-10-03 WO claimed
EP-4688773-A1 PROCESS FOR THE PREPARATION OF SUVOREXANT Biophore India Pharmaceuticals Pvt. Ltd. (IN) 2026-02-11 EP disclosed
CN-119264064-A Synthetic method of high chiral purity suvorexant intermediate 安徽联创生物医药股份有限公司 2025-01-07 CN disclosed
CN-119264064-A Synthetic method of high chiral purity suvorexant intermediate 安徽联创生物医药股份有限公司 2025-01-07 CN disclosed
WO-2024201424-A1 PROCESS FOR THE PREPARATION OF SUVOREXANT BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) 2024-10-03 WO disclosed
EP-3412665-B1 SUVOREXANT INTERMEDIATES AND PREPARATION METHODS THEREOF ZHEJIANG HUAHAI PHARM CO LTD (CN) 2021-03-03 EP disclosed
US-10618891-B2 Suvorexant intermediate and preparation method thereof ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) 2020-04-14 US disclosed
US-20190040052-A1 SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) 2019-02-07 US disclosed
WO-2017133620-A1 SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF 浙江华海药业股份有限公司 2017-08-10 WO disclosed
US-20160168138-A1 PROCESS FOR THE PREPARATION OF SUVOREXANT AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF SUVOREXANT REDDY S LAB LIMTED DR (IN) 2016-06-16 US disclosed
US-20160168138-A1 PROCESS FOR THE PREPARATION OF SUVOREXANT AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF SUVOREXANT REDDY S LAB LIMTED DR (IN) 2016-06-16 US disclosed
US-20160168138-A1 PROCESS FOR THE PREPARATION OF SUVOREXANT AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF SUVOREXANT REDDY S LAB LIMTED DR (IN) 2016-06-16 US disclosed
EP-3021851-A2 PROCESS FOR THE PREPARATION OF SUVOREXANT AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF SUVOREXANT Dr. Reddy's Laboratories Ltd. (IN) 2016-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190040052-A1 SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF COMT, KMO, CYP4B1 ACHE 1574/4885SIGMAR1 271/4885CCR3 2997/4885
US-10618891-B2 Suvorexant intermediate and preparation method thereof COMT, KMO, CYP4B1 ACHE 1574/4885SIGMAR1 271/4885CCR3 2997/4885
US-20160168138-A1 PROCESS FOR THE PREPARATION OF SUVOREXANT AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF SUVOREXANT KMO, HCRTR2, COMT ACHE 2288/4885SIGMAR1 284/4885CCR3 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.